Literature DB >> 14577520

Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation.

Patrizia Ferroni1, Stefania Basili, Francesca Martini, Cristiano M Cardarello, Fabrizio Ceci, Manuela Di Franco, Giuliano Bertazzoni, Pier Paolo Gazzaniga, Cesare Alessandri.   

Abstract

BACKGROUND: The finding that expression of metalloproteinases (MMPs) is induced in atherosclerotic plaques prone to rupture suggests the possibility that patients with atherosclerotic diseases would show enhanced blood levels of MMPs and that MMPs might represent a potential inflammatory risk factor for atherosclerosis. Therefore, the present study was aimed at verifying whether MMPs may represent sensitive markers of inflammation in patients with coronary artery disease.
METHODS: MMP-2, MMP-9, interleukin (IL)-6, C-reactive protein (CRP), and fibrinogen levels were measured in blood samples obtained from 66 cases with previous acute myocardial infarction and 66 control subjects similar for age, sex, and major atherosclerotic risk factors but without history or evidence of atherothrombotic diseases.
RESULTS: Biohumoral markers of inflammation and MMP-9 levels were significantly elevated in cases compared with controls (median values 40.6 versus 9.8 ng/mL; p < .0001), whereas MMP-2 levels did not differ between the two groups (median values 839 versus 873 ng/mL; p = .53). A direct correlation was found among MMP-9, CRP, IL-6, and fibrinogen levels. Conditional logistic regression analysis showed that MMP-9 is related to myocardial infarction (p = .006) even after adjusting for cardiovascular medications and CRP.
CONCLUSION: These findings suggest that measurement of serum MMP-9 levels may represent a novel marker of inflammation in patients with known coronary artery disease and might provide an index of plaque activity in this clinical setting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577520     DOI: 10.1136/jim-51-05-17

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  24 in total

1.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 2.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

3.  Environmental arsenic exposure and serum matrix metalloproteinase-9.

Authors:  Jefferey L Burgess; Margaret Kurzius-Spencer; Mary Kay O'Rourke; Sally R Littau; Jason Roberge; Maria Mercedes Meza-Montenegro; Luis Enrique Gutiérrez-Millán; Robin B Harris
Journal:  J Expo Sci Environ Epidemiol       Date:  2012-12-12       Impact factor: 5.563

4.  Plasma levels of matrix metalloproteinase 9 in patients undergoing off-pump coronary artery bypass grafting.

Authors:  Haiqing Li; Zhize Yuan; Sen Li; Quan Qi; Jun Liu; Mi Zhou; Junfeng Cai; Anqing Chen; Zhe Wang; Xiaofeng Ye; Qiang Zhao
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

5.  Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals.

Authors:  Lennart Nilsson; Per Eriksson; Pierre Cherfan; Lena Jonasson
Journal:  Inflammation       Date:  2011-08       Impact factor: 4.092

6.  Co-cultures of human coronary smooth muscle cells and dimethyl sulfoxide-differentiated HL60 cells upregulate ProMMP9 activity and promote mobility-modulation by reactive oxygen species.

Authors:  Yohann Bernard; Chantal Melchior; Eric Tschirhart; Jean-Luc Bueb
Journal:  Inflammation       Date:  2008-10       Impact factor: 4.092

7.  Evidence of inflammatory cell involvement in brain arteriovenous malformations.

Authors:  Yongmei Chen; Wei Zhu; Andrew W Bollen; Michael T Lawton; Nicholas M Barbaro; Christopher F Dowd; Tomoki Hashimoto; Guo-Yuan Yang; William L Young
Journal:  Neurosurgery       Date:  2008-06       Impact factor: 4.654

8.  NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease.

Authors:  Camilla Noelle Rathcke; Erik Kjøller; Niels Fogh-Andersen; Bo Zerahn; Henrik Vestergaard
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

9.  Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome.

Authors:  Giuseppe Derosa; Angela D'Angelo; Filippo Scalise; Maria A Avanzini; Carmine Tinelli; Emmanouil Peros; Elena Fogari; Arrigo F G Cicero
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

10.  Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?

Authors:  Ursula Hoffmann; Martina Brueckmann; Martin Borggrefe
Journal:  Crit Care       Date:  2009-12-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.